Figure 6.

Additive effect of MB07811 in combination with atorvastatin in normal dogs. (A) Animal-by-animal (n = 12) serum cholesterol at pre-dose (pre) and following 7 days of treatment (post) with MB07811, atorvastatin or atorvastatin + MB07811 in combination. Combined treatment resulted in a marked decrease in cholesterol regardless of baseline values in all animals. (B) Data shown are the average (n = 12) % changes in serum cholesterol following 7 days of treatment (post) compared with pre-dose levels taken just prior to the first dose of each cycle. Both MB07811 and atorvastatin given as monotherapy resulted in significant decreases in cholesterol compared with pre-dose levels (*P < 0.01). Notably, the combination treatment resulted in a significantly greater decrease in cholesterol compared with either MB07811 or atorvastatin given alone (**P < 0.01). Values are mean ± SEM.